Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Endocrine/metabolic disease

Diabetes

VEGF-B

Mouse studies suggest antagonizing VEGF-B could be useful for treating type 2 diabetes. In mouse models of the disease, Vegf-b knockouts or mice treated with an anti-Vegf-b mAb had lower lipid accumulation in peripheral tissues and greater glucose uptake than wild-type mice or mice given a control mAb. Next steps include completing preclinical toxicology studies with a humanized anti-VEGF-B mAb.
CSL Ltd. has the humanized mAb in preclinical development for cardiovascular and metabolic indications.

SciBX 5(41); doi:10.1038/scibx.2012.1085
Published online Oct. 18, 2012

Covered by issued and pending patents from CSL and the Ludwig Institute for Cancer Research Ltd.; available for partnering

Hagberg, C.E. et al. Nature; published online Sept. 26, 2012;
doi:10.1038/nature11464
Contact: Ulf Eriksson, Karolinska Institute, Stockholm, Sweden
e-mail:
ulf.pe.eriksson@ki.se